Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2−, node-positive, high-risk early breast cancer in Italy

por Davie, Alison, Traoré, Sory, Giovannitti, Massimo, Pompilio, Giuseppe, Lambton, Mark, Cakar, Esra, Chatterjee, Anuja
Publicado 2023